← Scroll for more →
Exelixis, Inc. (EXEL)
Biological Products, (No Diagnostic Substances)
Latest Price
$58.41
TTM P/E
18.31
Normalized P/E
35.38
Div Yield
--
Book Value
7.44
P/B Ratio
7.85
Valuation metrics
adjust assumptions →EPS: $2.78
Book value / share: $8.23
Formula: √(22.5 × EPS × BVPS)
Graham Number
$22.69
61% downside
Norm. op. income: $287M (median of 5yr)
Tax rate: 45%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$10.04
83% downside
Base FCF: $337M (median of recent 5yr)
Growth: -7%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$13.57
77% downside
EPS: $2.78
Target P/E: 35×
Formula: EPS × P/E
P/E Fair Value
$97.30
+67% upside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 29.08M | $1.58B | 11.68% | -1.74M | 2026-06-30 |
| Farallon Capital Management, L.L.C. | 13.47M | $732.0M | 5.41% | -- | 2026-06-30 |
| Renaissance Technologies LLC | 13.43M | $730.0M | 5.40% | -299.0K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 12.04M | $655.0M | 4.84% | -42.2K | 2026-06-30 |
| AQR Capital Management LLC | 11.02M | $598.0M | 4.43% | -2.07M | 2026-06-30 |
| Vanguard Capital Management LLC | 10.95M | $595.0M | 4.40% | -308.0K | 2026-06-30 |
| State Street Corp | 9.97M | $542.0M | 4.01% | -328.4K | 2026-06-30 |
| Fuller & Thaler Asset Management, Inc. | 8.93M | $485.0M | 3.59% | +387.2K | 2026-06-30 |
| Lsv Asset Management | 8.15M | $443.0M | 3.27% | +400.8K | 2026-06-30 |
| Geode Capital Management, LLC | 7.65M | $416.0M | 3.07% | -145.3K | 2026-06-30 |